Positron emission tomography imaging of D2/3 agonist binding in healthy human subjects with the radiotracer [11C]‐N‐propyl‐norapomorphine: Preliminary evaluation and reproducibility studies

(−)‐N‐[11C]‐propyl‐norapomorphine (NPA) is a full dopamine D2/3 receptor agonist radiotracer suitable for imaging D2/3 receptors configured in a state of high affinity for agonists using positron emission tomography. The aim of the present study was to define the optimal analytic method to derive accurate and reliable D2/3 receptor parameters with [11C]NPA.

[1]  Sylvain Houle,et al.  High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO , 2006, Biological Psychiatry.

[2]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  Alan A. Wilson,et al.  First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study , 2008, Neuropsychopharmacology.

[4]  A. Dagher,et al.  Conditioned Dopamine Release in Humans: A Positron Emission Tomography [11C]Raclopride Study with Amphetamine , 2007, The Journal of Neuroscience.

[5]  P. Sokoloff,et al.  A functional test identifies dopamine agonists selective for D3 versus D2 receptors. , 1995, Neuroreport.

[6]  Donald Sashin,et al.  Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain , 1998, Synapse.

[7]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Mark Slifstein,et al.  Quantitative analysis of (-)-N-(11)C-propyl-norapomorphine in vivo binding in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Alan A. Wilson,et al.  Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  Mark Slifstein,et al.  Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  J. Seibyl,et al.  SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Mark Slifstein,et al.  Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  D. Shibata,et al.  MR volumetric analysis of the human basal ganglia: normative data. , 2000, Academic radiology.

[14]  H. Soininen,et al.  MR volumetric analysis of the human entorhinal, perirhinal, and temporopolar cortices. , 1998, AJNR. American journal of neuroradiology.

[15]  K Suzuki,et al.  Reproducibility of [11C]FLB 457 binding in extrastriatal regions , 2001, Nuclear medicine communications.

[16]  R. Kirk.  Experimental Design: Procedures for the Behavioral Sciences , 1970 .

[17]  Ariel Graff-Guerrero,et al.  Brain region binding of the D2/3 agonist [11C]‐(+)‐PHNO and the D2/3 antagonist [11C]raclopride in healthy humans , 2008, Human brain mapping.

[18]  Mark Slifstein,et al.  In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐raclopride , 2004, Synapse.

[19]  Christer Halldin,et al.  Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. Kebabian,et al.  S-(+)-aporphines are not selective for human D3 dopamine receptors , 1994, Cellular and Molecular Neurobiology.

[21]  M Laruelle,et al.  Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.

[22]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[23]  S. Zoghbi,et al.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.

[24]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[25]  S. Haber,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  Kenneth Levenberg.  A METHOD FOR THE SOLUTION OF CERTAIN NON – LINEAR PROBLEMS IN LEAST SQUARES , 1944 .

[27]  J J DiStefano,et al.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.

[28]  Mark Slifstein,et al.  Measurement of the Proportion of D2 Receptors Configured in State of High Affinity for Agonists in Vivo: A Positron Emission Tomography Study Using [11C]N-Propyl-norapomorphine and [11C]Raclopride in Baboons , 2005, Journal of Pharmacology and Experimental Therapeutics.

[29]  M. Knowles,et al.  Expression and pharmacological characterization of the human D3 dopamine receptor. , 1994, The Journal of pharmacology and experimental therapeutics.

[30]  S. J. Gatley,et al.  Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain , 1997, Psychopharmacology.

[31]  D. Hwang,et al.  (−)-N-[11C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptors , 2000 .

[32]  Osama Mawlawi,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  N. Ginovart,et al.  Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2high and D3high receptors , 2005, Synapse.

[34]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[35]  P. Strange,et al.  Mechanisms of Agonist Action at D2 Dopamine Receptors , 2004, Molecular Pharmacology.

[36]  P. Strange,et al.  Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. , 2004, Biochemical pharmacology.

[37]  H. Akaike.  A new look at the statistical model identification , 1974 .

[38]  R. Narendran,et al.  Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]‐(+)‐PHNO is a D3 receptor preferring agonist in vivo , 2006, Synapse.

[39]  J S Fowler,et al.  Cocaine abusers do not show loss of dopamine transporters with age. , 1997, Life sciences.

[40]  M Slifstein,et al.  Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.